II

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$64.18M
EPS-10.7600
P/E Ratio-0.53
Earnings Date07/23/2026

ima

Accumulated Other Comprehensive Income (Loss)

Last Annual Value

87.00K

3-Year CAGR

28%

5-Year CAGR

%

10-Year CAGR

%

II

ImageneBio Inc Competitors Analysis of Accumulated Other Comprehensive Income (Loss)

IMA · NASDAQ
CompanyAccumulated Other Comprehensive Income (Loss)
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
87.00K
N/AN/AN/A 
-35.00K
N/AN/AN/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
102.00K
N/AN/AN/A
3.22M
7.0%N/AN/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
2.65M
-11.0%N/A41.4%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
-304.00
N/AN/AN/A
-1.00K
N/AN/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
-3.00K
N/AN/AN/A
19.00K
-3.3%N/AN/A
-202.00K
N/AN/AN/A
6.00K
N/AN/AN/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.69